Susan Landau
UC Berkeley and Lawrence Berkeley National LabBerkeley, United States
331203 RESULTS
UC Berkeley and Lawrence Berkeley National LabBerkeley, United States
RESEARCH NEWS 2014-04-02 Research News In Alzheimer’s disease, cognitive decline correlates most closely with the loss of synapses, but exactly what makes them vanish remains a mystery. Now, in the April 2 Neuron, researchers led by Ilya Bezprozvanny at the University of Texas So
PAPER Bourne J, Harris KM
COMMENT The community as a whole—independent researchers, colleagues and competitors alike—are eagerly awaiting a successful AD trial, hence there is widespread disappointment about the results of this 52-week study of PBT2 in 42 prodromal AD or mild AD patients.
PAPER Kaye JA, Moore MM, Dame A, Quinn J, Camicioli R, Howieson D, Corbridge E, Care B, Nesbit G, Sexton G
COMMENT Comment posted by the editors on behalf of Xiao-Jiang Li, Distinguished Professor of Human Genetics, Emory University School of Medicine: I read this paper and found it an interesting work. The new finding is that improving glial function can alleviate mo
United States
COMMENT The big picture here is that Prana’s only prior Phase 2 trial with PBT2 — completed in 2007 with 78 mild AD patients treated for 12 weeks — showed lower CSF Aβ42 and nominally significant effects on verbal fluency and working memory. A reasonable developm
PAPER Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV, Khakh BS
Biogen
Professional Regulation, IIT BombayMt Prospect, United States
PAPER Belluti F, De Simone A, Tarozzi A, Bartolini M, Djemil A, Bisi A, Gobbi S, Montanari S, Cavalli A, Andrisano V, Bottegoni G, Rampa A
PAPER Hedera P, Friedman JH
No filters selected